These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32273279)

  • 21. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer.
    Mikami H; Feng S; Matsuda Y; Ishii S; Naoi S; Azuma Y; Nagano H; Asanuma K; Kayukawa Y; Tsunenari T; Kamikawaji S; Iwabuchi R; Shinozuka J; Yamazaki M; Kuroi H; Ho SSW; Gan SW; Chichili P; Pang CL; Yeo CY; Shimizu S; Hironiwa N; Kinoshita Y; Shimizu Y; Sakamoto A; Muraoka M; Takahashi N; Kawa T; Shiraiwa H; Mimoto F; Kashima K; Kamata-Sakurai M; Ishikawa S; Aburatani H; Kitazawa T; Igawa T
    Cancer Immunol Res; 2024 Jun; 12(6):719-730. PubMed ID: 38558120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment.
    Kuang Z; Pu P; Wu M; Wu Z; Wang L; Li Y; Zhang S; Jing H; Wu W; Chen B; Liu J
    Mol Cancer Ther; 2020 Dec; 19(12):2564-2574. PubMed ID: 32999045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
    Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
    Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
    Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
    Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
    Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    Mardiana S; John LB; Henderson MA; Slaney CY; von Scheidt B; Giuffrida L; Davenport AJ; Trapani JA; Neeson PJ; Loi S; Haynes NM; Kershaw MH; Beavis PA; Darcy PK
    Cancer Res; 2017 Mar; 77(6):1296-1309. PubMed ID: 28082401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
    Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
    Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
    Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
    Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
    Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
    Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
    Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
    Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
    Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-VEGF Treatment Enhances CD8
    de Almeida PE; Mak J; Hernandez G; Jesudason R; Herault A; Javinal V; Borneo J; Kim JM; Walsh KB
    Cancer Immunol Res; 2020 Jun; 8(6):806-818. PubMed ID: 32238381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.